Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vericel (VCEL – Research Report), Addus Homecare (ADUS – Research Report) and Baxter International (BAX – Research Report).
Vericel (VCEL)
BTIG analyst Ryan Zimmerman maintained a Buy rating on Vericel today and set a price target of $34.00. The company’s shares closed last Wednesday at $32.57.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
Vericel has an analyst consensus of Strong Buy, with a price target consensus of $41.25, representing a 29.4% upside. In a report issued on July 20, Truist Financial also maintained a Buy rating on the stock with a $33.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Addus Homecare (ADUS)
In a report released today, Ben Hendrix from RBC Capital maintained a Buy rating on Addus Homecare, with a price target of $110.00. The company’s shares closed last Wednesday at $93.70.
According to TipRanks.com, Hendrix is a 1-star analyst with an average return of
Currently, the analyst consensus on Addus Homecare is a Strong Buy with an average price target of $110.50, representing a 15.3% upside. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $130.00 price target.
Baxter International (BAX)
In a report released today, Amit Hazan from Goldman Sachs maintained a Sell rating on Baxter International, with a price target of $60.00. The company’s shares closed last Wednesday at $58.46, close to its 52-week low of $57.92.
According to TipRanks.com, Hazan is a 4-star analyst with an average return of
Currently, the analyst consensus on Baxter International is a Moderate Buy with an average price target of $70.73.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VCEL: